Skip to search formSkip to main contentSkip to account menu

CKD 516

Known as: CKD-516, CKD516, Tubulin Polymerization Inhibitor CKD-516 
A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting… 
National Institutes of Health

Related topics

Related topics

1 relation
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Concordance of dietary sodium intake and concomitant phosphate load: Implications for sodium interventions.
Highly Cited
2015
Highly Cited
2015
Impaired vascular function contributes to exercise intolerance in chronic kidney disease.
BACKGROUND Exercise intolerance is an important feature in patients with chronic kidney disease (CKD) and is prognostic for both… 
2015
2015
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Purpose CKD-516 is a newly developed vascular disrupting agent. This phase I dose-escalation study of CKD-516 was conducted to… 
Review
2015
Review
2015
Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Tumor vasculature is an important target in cancer treatment. Two distinct vasculartargeting therapeutic strategies are applied… 
Highly Cited
2014
Highly Cited
2014
Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors.
PURPOSE To evaluate the diagnostic value of intravoxel incoherent motion (IVIM) diffusion-weighted (DW) magnetic resonance (MR… 
2013
2013
Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI
SummaryVascular disrupting agents (VDAs) are new class of anti-cancer drugs targeting pre-existing tumor vasculature which lead… 
2013
2013
Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors
Purpose: To evaluate the usefulness of dynamic contrast-enhanced ultrasonography (DCE-US) in the early quantification of… 
Highly Cited
2010
Highly Cited
2010
Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
Tubulin polymerization inhibitors had emerged as one of promising anticancer therapeutics because of their dual mechanism of… 
2010
2010
Discovery of a potent tubulin polymerization inhibitor: synthesis and evaluation of water-soluble prodrugs of benzophenone analog.
2003
2003
The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.
BACKGROUND Provision of adequate iron to support erythropoiesis in patients with chronic kidney disease (CKD) is time consuming… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)